{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:32Z","timestamp":1791912512571,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00401-020-02147-5","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T07:02:47Z","timestamp":1583823767000},"page":"1119-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Complement deposition at the neuromuscular junction in seronegative myasthenia gravis"],"prefix":"10.1007","volume":"139","author":[{"given":"Sarah","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schuelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Carsten","family":"R\u00fcckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Hilmar","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"issue":"5","key":"2147_CR1","first-page":"267","volume":"52","author":"AG Engel","year":"1977","unstructured":"Engel AG, Lambert EH, Howard FM (1977) Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52(5):267\u2013280","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2147_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"2","key":"2147_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69(2):418\u2013422. https:\/\/doi.org\/10.1002\/ana.22312","journal-title":"Ann Neurol"},{"issue":"3","key":"2147_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7(3):365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"issue":"12","key":"2147_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"Pt 4","key":"2147_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","volume":"135","author":"R Klooster","year":"2012","unstructured":"Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ et al (2012) Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135(Pt 4):1081\u20131101. https:\/\/doi.org\/10.1093\/brain\/aws025","journal-title":"Brain"},{"issue":"11","key":"2147_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/wnl.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26(11):1054\u20131059. https:\/\/doi.org\/10.1212\/wnl.26.11.1054","journal-title":"Neurology"},{"key":"2147_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.01.011","author":"PM Rodriguez Cruz","year":"2015","unstructured":"Rodriguez Cruz PM, Huda S, Lopez-Ruiz P, Vincent A (2015) Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2015.01.011","journal-title":"Exp Neurol"},{"issue":"11","key":"2147_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/archneur.1975.00490530101013","volume":"32","author":"LZ Stern","year":"1975","unstructured":"Stern LZ, Gruener R, Anderson RM (1975) External intercostal muscle biopsy. Arch Neurol 32(11):779\u2013780. https:\/\/doi.org\/10.1001\/archneur.1975.00490530101013","journal-title":"Arch Neurol"},{"issue":"9","key":"2147_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1136\/jnnp.38.9.900","volume":"38","author":"LZ Stern","year":"1975","unstructured":"Stern LZ, Payne CM, Gruener R, Anderson RM, Hannapel LK (1975) Intercostal muscle biopsy in human neuromuscular disease. Histochemical and electron microscopic studies. J Neurol Neurosurg Psychiatry 38(9):900\u2013910. https:\/\/doi.org\/10.1136\/jnnp.38.9.900","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2147_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1212\/wnl.39.10.1359","volume":"39","author":"M Tsujihata","year":"1989","unstructured":"Tsujihata M, Yoshimura T, Satoh A, Kinoshita I, Matsuo H, Mori M et al (1989) Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 39(10):1359\u20131363. https:\/\/doi.org\/10.1212\/wnl.39.10.1359","journal-title":"Neurology"},{"issue":"1","key":"2147_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","volume":"1413","author":"A Vincent","year":"2018","unstructured":"Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez Cruz PM et al (2018) Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci 1413(1):143\u2013153. https:\/\/doi.org\/10.1111\/nyas.13592","journal-title":"Ann N Y Acad Sci"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-020-02147-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-020-02147-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-020-02147-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T19:32:19Z","timestamp":1615318339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-020-02147-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1007\/s00401-020-02147-5","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sarah Hoffmann has received speaker honoraria from Alexion. Lutz Harms received honoraria from Alexion for speaking and consulting services. Markus Schuelke has no conflicts of interest. Jens-Carsten R\u00fcckert has no conflicts of interest. Hans-Hilmar Goebel has no conflicts of interest. Werner Stenzel has no conflicts of interest. Andreas Meisel received speaker honoraria from Alexion, GRIFOLS and Hormosan. He received honoraria from Alexion, MorphoSys and Vitaccess for consulting services and financial research support from Octapharma and Alexion. Andreas Meisel is chairman of the medical advisory board of the German Myasthenia Gravis Society (Deutsche Myasthenie Gesellschaft, DMG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}